The Thompson Lab

Publications

2011

Protein deiminases: New players in the developmentally regulated loss of neural regenerative ability.
Lange S, Gögel S, Leung KY, Vernay B, Nicholas AP, Causey CP, Thompson PR, Greene ND, Ferretti P.
Dev Biol. 2011 Apr 22.

Autodeimination of protein arginine deiminase 4 alters protein-protein interactions but not activity.
Slack JL, Jones LE, Bhatia MM, Thompson PR.
Biochemistry. 2011 May 17;50(19):3997-4010. Epub 2011 Apr 20.

Mechanistic studies on transcriptional coactivator protein arginine methyltransferase 1.
Rust HL, Zurita-Lopez CI, Clarke S, Thompson PR.
Biochemistry. 2011 Apr 26;50(16):3332-45. Epub 2011 Apr 1.

Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor.
Chumanevich AA, Causey CP, Knuckley BA, Jones JE, Poudyal D, Chumanevich AP, Davis T, Matesic LE, Thompson PR, Hofseth LJ.
Am J Physiol Gastrointest Liver Physiol. 2011 Jun;300(6):G929-38. Epub 2011 Mar 17.

Boronic Acid functionalized peptidyl synthetic lectins: combinatorial library design, Peptide sequencing, and selective glycoprotein recognition.
Bicker KL, Sun J, Lavigne JJ, Thompson PR.
ACS Comb Sci. 2011 May 9;13(3):232-43. Epub 2011 Mar 25.

N-α-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis.
Willis VC, Gizinski AM, Banda NK, Causey CP, Knuckley B, Cordova KN, Luo Y, Levitt B, Glogowska M, Chandra P, Kulik L, Robinson WH, Arend WP, Thompson PR, Holers VM.
J Immunol. 2011 Apr 1;186(7):4396-404. Epub 2011 Feb 23.

Development and use of clickable activity based protein profiling agents for protein arginine deiminase 4.
Slack JL, Causey CP, Luo Y, Thompson PR.
ACS Chem Biol. 2011 May 20;6(5):466-76. Epub 2011 Feb 7.

2010

Mechanistic studies of agmatine deiminase from multiple bacterial species.
Jones JE, Dreyton CJ, Flick H, Causey CP, Thompson PR.
Biochemistry. 2010 Nov 2;49(43):9413-23.

A fluopol-ABPP HTS assay to identify PAD inhibitors.
Knuckley B, Jones JE, Bachovchin DA, Slack J, Causey CP, Brown SJ, Rosen H, Cravatt BF, Thompson PR.
Chem Commun (Camb). 2010 Oct 14;46(38):7175-7. Epub 2010 Aug 25.

Protein arginine deiminase 4: a target for an epigenetic cancer therapy.
Slack JL, Causey CP, Thompson PR.
Cell Mol Life Sci. 2011 Feb;68(4):709-20. Epub 2010 Aug 13.

A combinatorial approach to characterize the substrate specificity of protein arginine methyltransferase 1.
Bicker KL, Obianyo O, Rust HL, Thompson PR.
Mol Biosyst. 2011 Jan;7(1):48-51. Epub 2010 Jul 6.

A chloroacetamidine-based inactivator of protein arginine methyltransferase 1: design, synthesis, and in vitro and in vivo evaluation.
Obianyo O, Causey CP, Osborne TC, Jones JE, Lee YH, Stallcup MR, Thompson PR.
Chembiochem. 2010 Jun 14;11(9):1219-23. No abstract available.

Substrate specificity and kinetic studies of PADs 1, 3, and 4 identify potent and selective inhibitors of protein arginine deiminase 3.
Knuckley B, Causey CP, Jones JE, Bhatia M, Dreyton CJ, Osborne TC, Takahara H, Thompson PR.
Biochemistry. 2010 Jun 15;49(23):4852-63.

2009

Characterization and inactivation of an agmatine deiminase from Helicobacter pylori.
Jones JE, Causey CP, Lovelace L, Knuckley B, Flick H, Lebioda L, Thompson PR.
Bioorg Chem. 2010 Apr;38(2):62-73. Epub 2009 Nov 29.

Haloacetamidine-based inactivators of protein arginine deiminase 4 (PAD4): evidence that general acid catalysis promotes efficient inactivation.
Knuckley B, Causey CP, Pellechia PJ, Cook PF, Thompson PR.
Chembiochem. 2010 Jan 25;11(2):161-5.

Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential.
Jones JE, Causey CP, Knuckley B, Slack-Noyes JL, Thompson PR.
Curr Opin Drug Discov Devel. 2009 Sep;12(5):616-27. Review.

2008

An improved synthesis of haloaceteamidine-based inactivators of protein arginine deiminase 4 (PAD4).
Causey CP, Thompson PR.
Tetrahedron Lett. 2008 Jul 7;49(28):4383-4385.

The tomato brassinosteroid receptor BRI1 increases binding of systemin to tobacco plasma membranes, but is not involved in systemin signaling.
Malinowski R, Higgins R, Luo Y, Piper L, Nazir A, Bajwa VS, Clouse SD, Thompson PR, Stratmann JW.
Plant Mol Biol. 2009 Jul;70(5):603-16. Epub 2009 Apr 29.

The protein acetyltransferase ARD1: a novel cancer drug target?
Arnesen T, Thompson PR, Varhaug JE, Lillehaug JR.
Curr Cancer Drug Targets. 2008 Nov;8(7):545-53. Review.

Kinetic mechanism of protein arginine methyltransferase 1.
Obianyo O, Osborne TC, Thompson PR.
Biochemistry. 2008 Sep 30;47(39):10420-7. Epub 2008 Sep 5.

Regulation of p53 target gene expression by peptidylarginine deiminase 4.
Li P, Yao H, Zhang Z, Li M, Luo Y, Thompson PR, Gilmour DS, Wang Y.
Mol Cell Biol. 2008 Aug;28(15):4745-58. Epub 2008 May 27.

Histone Arg modifications and p53 regulate the expression of OKL38, a mediator of apoptosis.
Yao H, Li P, Venters BJ, Zheng S, Thompson PR, Pugh BF, Wang Y.
J Biol Chem. 2008 Jul 18;283(29):20060-8. Epub 2008 May 22.

In situ generation of a bisubstrate analogue for protein arginine methyltransferase 1.
Osborne T, Roska RL, Rajski SR, Thompson PR.
J Am Chem Soc. 2008 Apr 9;130(14):4574-5. Epub 2008 Mar 14.

The structural basis of protein acetylation by the p300/CBP transcriptional coactivator.
Liu X, Wang L, Zhao K, Thompson PR, Hwang Y, Marmorstein R, Cole PA.
Nature. 2008 Feb 14;451(7180):846-50.

Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors.
Knuckley B, Luo Y, Thompson PR.
Bioorg Med Chem. 2008 Jan 15;16(2):739-45. Epub 2007 Oct 13.

2007

Protein arginine methyltransferase 1: positively charged residues in substrate peptides distal to the site of methylation are important for substrate binding and catalysis.
Osborne TC, Obianyo O, Zhang X, Cheng X, Thompson PR.
Biochemistry. 2007 Nov 20;46(46):13370-81. Epub 2007 Oct 26.

Peptide borono lectins (PBLs): a new tool for glycomics and cancer diagnostics.
Zou Y, Broughton DL, Bicker KL, Thompson PR, Lavigne JJ.
Chembiochem. 2007 Nov 23;8(17):2048-51. No abstract available.

A selective chemical probe for coenzyme A-requiring enzymes.
Hwang Y, Thompson PR, Wang L, Jiang L, Kelleher NL, Cole PA.
Angew Chem Int Ed Engl. 2007;46(40):7621-4. No abstract available.

Protein arginine deiminase 4: evidence for a reverse protonation mechanism.
Knuckley B, Bhatia M, Thompson PR.
Biochemistry. 2007 Jun 5;46(22):6578-87. Epub 2007 May 12.

Methyllysine analogs: rewriting the code.
Bhatia M, Thompson PR.
Nat Chem Biol. 2007 May;3(5):249-50. No abstract available.

2006

Histone citrullination by protein arginine deiminase: is arginine methylation a green light or a roadblock?
Thompson PR, Fast W.
ACS Chem Biol. 2006 Aug 22;1(7):433-41. Review.

Activity-based protein profiling reagents for protein arginine deiminase 4 (PAD4): synthesis and in vitro evaluation of a fluorescently labeled probe.
Luo Y, Knuckley B, Bhatia M, Pellechia PJ, Thompson PR.
J Am Chem Soc. 2006 Nov 15;128(45):14468-9.

Inhibitors and inactivators of protein arginine deiminase 4: functional and structural characterization.
Luo Y, Arita K, Bhatia M, Knuckley B, Lee YH, Stallcup MR, Sato M, Thompson PR.
Biochemistry. 2006 Oct 3;45(39):11727-36.

A fluoroacetamidine-based inactivator of protein arginine deiminase 4: design, synthesis, and in vitro and in vivo evaluation.
Luo Y, Knuckley B, Lee YH, Stallcup MR, Thompson PR.
J Am Chem Soc. 2006 Feb 1;128(4):1092-3.

2005

Kinetic characterization of protein arginine deiminase 4: a transcriptional corepressor implicated in the onset and progression of rheumatoid arthritis.
Kearney PL, Bhatia M, Jones NG, Yuan L, Glascock MC, Catchings KL, Yamada M, Thompson PR.
Biochemistry. 2005 Aug 9;44(31):10570-82.

2004

LCC15-MB cells are MDA-MB-435: a review of misidentified breast and prostate cell lines.
Thompson EW, Waltham M, Ramus SJ, Hutchins AM, Armes JE, Campbell IG, Williams ED, Thompson PR, Rae JM, Johnson MD, Clarke R.
Clin Exp Metastasis. 2004;21(6):535-41.

Bisubstrate analogue structure-activity relationships for p300 histone acetyltransferase inhibitors.
Sagar V, Zheng W, Thompson PR, Cole PA.
Bioorg Med Chem. 2004 Jun 15;12(12):3383-90.

Regulation of the p300 HAT domain via a novel activation loop.
Thompson PR, Wang D, Wang L, Fulco M, Pediconi N, Zhang D, An W, Ge Q, Roeder RG, Wong J, Levrero M, Sartorelli V, Cotter RJ, Cole PA.
Nat Struct Mol Biol. 2004 Apr;11(4):308-15. Epub 2004 Mar 7.

Selective HAT inhibitors as mechanistic tools for protein acetylation.
Zheng Y, Thompson PR, Cebrat M, Wang L, Devlin MK, Alani RM, Cole PA.
Methods Enzymol. 2004;376:188-99. Review. No abstract available.

2003

Synthesis and analysis of potential prodrugs of coenzyme A analogues for the inhibition of the histone acetyltransferase p300.
Cebrat M, Kim CM, Thompson PR, Daugherty M, Cole PA.
Bioorg Med Chem. 2003 Jul 31;11(15):3307-13.

2002

Mechanism of aminoglycoside antibiotic kinase APH(3')-IIIa: role of the nucleotide positioning loop.
Thompson PR, Boehr DD, Berghuis AM, Wright GD.
Biochemistry. 2002 Jun 4;41(22):7001-7.

2001

Probing the mechanism of enzymatic phosphoryl transfer with a chemical trick.
Thompson PR, Cole PA.
Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8170-1. Review. No abstract available.

Transcriptional coactivator protein p300. Kinetic characterization of its histone acetyltransferase activity.
Thompson PR, Kurooka H, Nakatani Y, Cole PA.
J Biol Chem. 2001 Sep 7;276(36):33721-9. Epub 2001 Jul 9.

Molecular mechanism of aminoglycoside antibiotic kinase APH(3')-IIIa: roles of conserved active site residues.
Boehr DD, Thompson PR, Wright GD.
J Biol Chem. 2001 Jun 29;276(26):23929-36. Epub 2001 Feb 27.